| Literature DB >> 28693358 |
Xuedan Huang1, Mingzhu Xu1, Tatsuya Shirahata1, Wei Li2, Kazuo Koike2, Akiko Kojima-Yuasa3, Isao Yuasa3, Yoshinori Kobayashi1.
Abstract
There is no drug administration-approved therapy for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In this study, eight compounds, gallic acid (1), methyl gallate (2), corilagin (3), 3,4,8,9,10-pentahydroxydibenzo[b,d]pyran-6-one (4), repandinin B (5), (Z)-3-hexenyl-β-D-glucopyranoside (6), (+)-lyoniresinol-3α-O-α-L-rhamnopyranoside (7) and mallophenol A (8) were isolated from the active fractions of Mallotus furetianus. Three compounds, (6, 7 and 8) revealed potent anti-steatosis activity in the oleic acid (OA)-induced steatosis cell model, with the minimum effective concentration of 0.05 (6), 0.0005 (7) and 0.0005 (8) μg/mL, which were much lower than the control compound, fibrate (72.4 μg/mL).Entities:
Keywords: (+)-lyoniresinol-3α-O-α-L-rhamnopyranoside; (Z)-3-hexenyl-β-D-glucopyranoside; Mallotus furetianus; anti-steatosis; mallophenol A
Mesh:
Substances:
Year: 2017 PMID: 28693358 DOI: 10.1080/14786419.2017.1350664
Source DB: PubMed Journal: Nat Prod Res ISSN: 1478-6419 Impact factor: 2.861